The findings in this study prove the principle that immunotherapy with an oncolytic NDV expressing the DC chemokine MIP-3α (NDV-MIP3α) enhances the production of antitumor immunities and reversely modulates the tumor immunosuppressive microenvironments. This evidence concerns the gene CCL20 and neoplasm.